Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 212

Sort by

Sort Order Select

Journal Articles

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Blood (2023) 141 (20): 2508–2519.

https://doi.org/10.1182/blood.2022015418

Published: 2023

Includes: Supplemental data

Journal Articles

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

Johanna Melo-Cardenas, Lavanya Bezavada, Jeremy Chase Crawford, Sandeep Gurbuxani, Anitria Cotton, Guolian Kang, Jeffrey Gossett, Christian Marinaccio, Rona Weinberg, Ronald Hoffman, Anna Rita Migliaccio, Yan Zheng, Marta Derecka, Ciro R. Rinaldi, John D. Crispino

Blood (2022) 140 (26): 2805–2817.

https://doi.org/10.1182/blood.2022017326

Published: 2022

Includes: Supplemental data

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Michal Bar-Natan, John Mascarenhas, Aaron T. Gerds, Ruben Mesa, Vikas Gupta, Marina Kremyanskaya, Mikaela Dougherty, Frank Fabris, Kathryn Johnson, Ashley Yu, Heidi E. Kosiorek, Carolyn Mead-Harvey, Amylou C. Dueck, Ronald Hoffman, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 3988–3990.

https://doi.org/10.1182/blood-2022-164678

Published: 2022

Journal Articles

Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy

Min Lu, Christoph Schaniel, Jeff Vierstra, Lijuan Xia, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 8625–8626.

https://doi.org/10.1182/blood-2022-170704

Published: 2022

Journal Articles

Pharmacological Disruption of the Interplay between HDM2-p53 and NFκB Depletes Myelofibrosis Progenitor/Stem Cells and Dampens the Accompanying Inflammatory Milieu

Min Lu, Lijuan Xia, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 3069–3070.

https://doi.org/10.1182/blood-2022-169781

Published: 2022

Journal Articles

Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis

Rebecca Austin, Madeline Kowalski, Xiaoli Wang, Bettina Nadorp, Audrey Lasry, Zhengxi Sun, Julia Rojo-Tomillo, Andrew Davis, Dimitrios Papaioannou, Rahul Satija, Ioannis Aifantis, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 9584–9585.

https://doi.org/10.1182/blood-2022-170220

Published: 2022

Journal Articles

ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis

Maayan Levy, Gino Ferraro, Li Li, Yongshuai Han, Lilian Varricchio, Sara Fournier, Xiuli An, Ronald Hoffman, Adrian Fretland, Anne Roulston, Yelena Ginzburg

Blood (2022) 140 (Supplement 1): 8194–8195.

https://doi.org/10.1182/blood-2022-169951

Published: 2022

Journal Articles

Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis

Bridget K Marcellino, Cara Clementelli, Kristin Beaumont, Christoph Schaniel, Min Lu, Karie Chen, Adena Russel, Ayman Mohammad, Daniel I Nathan, Jake Aronin, Alan H. Shih, Robert Sebra, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 797–798.

https://doi.org/10.1182/blood-2022-170232

Published: 2022

Journal Articles

Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Srdan Verstovsek, Andrew Kuykendall, Ronald Hoffman, Steffen Koschmieder, Francesco Passamonti, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 3929–3931.

https://doi.org/10.1182/blood-2022-163755

Published: 2022

Journal Articles

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera

Naveen Pemmaraju, Srdan Verstovsek, Marina Kremyanskaya, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 6835–6837.

https://doi.org/10.1182/blood-2022-163742

Published: 2022

Journal Articles

Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment

Aaron T. Gerds, Jason Gotlib, Jeanne M. Palmer, Naveen Pemmaraju, Prithviraj Bose, Yelena Ginzburg, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 12241–12243.

https://doi.org/10.1182/blood-2022-163847

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

High Throughput Single-Cell Simultaneous Genotyping and Chromatin Accessibility Reveals Genotype to Phenotype Relationship in Human Myeloproliferation

Robert M. Myers, Franco Izzo, Tamara Prieto, Eleni Mimitou, Ramya Raviram, Ronan Chaligne, Ronald Hoffman, Maximilian Stahl, Omar Abdel-Wahab, Bridget Marcellino, Peter Smibert, Dan A. Landau

Blood (2021) 138 (Supplement 1): 678.

https://doi.org/10.1182/blood-2021-149226

Published: 2021

Journal Articles

Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model

Xiaoli Wang, Cing Siang Hu, Virginia Gillespie, Cecile Marie Krejsa, Ronald Hoffman

Blood (2021) 138 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2021-153071

Published: 2021

Journal Articles

Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR- mutated Essential Thrombocythemia (ET) Patients

Shira Rosenberg, Andrea Kubas-Meyer, Neelang Parghi, Nathaniel D. Omans, Neville Dusaj, Paulina Chamely, Eleni Mimitou, Amylou C. Dueck, Heidi E. Kosiorek, Rona Singer Weinberg, Peter Smibert, Ronan Chaligne, Dan A. Landau, Ronald Hoffman, Anna S Nam

Blood (2021) 138 (Supplement 1): 57.

https://doi.org/10.1182/blood-2021-150745

Published: 2021

Journal Articles

Development of an MDM2 Degrader for Treatment of Acute Leukemias

Bridget Marcellino, Xiaobao Yang, He Chen, Karie Chen, Claudia Brady, Cara Clementelli, Zhijun Li, Ronald Hoffman, Jing Liu, H Ümit Kaniskan, Yue Xiong, Jian Jin, Alan H. Shih

Blood (2021) 138 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2021-147522

Published: 2021

Journal Articles

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Srdan Verstovsek, Andrew T. Kuykendall, Ronald Hoffman, Yelena Ginzburg, Naveen Pemmaraju, Frank Valone, Nishit B Modi, Sarita Khanna, Paula G. O'Connor, Suneel K Gupta, Jean-Jacques Kiladjian

Blood (2021) 138 (Supplement 1): 1504.

https://doi.org/10.1182/blood-2021-149219

Published: 2021

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

NARROW

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy

Pharmacological Disruption of the Interplay between HDM2-p53 and NFκB Depletes Myelofibrosis Progenitor/Stem Cells and Dampens the Accompanying Inflammatory Milieu

Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis

ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis

Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis

Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera

Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

High Throughput Single-Cell Simultaneous Genotyping and Chromatin Accessibility Reveals Genotype to Phenotype Relationship in Human Myeloproliferation

Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model

Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR- mutated Essential Thrombocythemia (ET) Patients

Development of an MDM2 Degrader for Treatment of Acute Leukemias

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only